About Us

BioSpeedia is a spin-off from Institut Pasteur and was founded by its two former renowned scientists in 2011:  Evelyne Begaud, President and Yves Germani, Chief Scientific Officer.

Institut Pasteur is the premier non-profit foundation that was founded in 1887 and has since originated 10 Nobel Prizes.

Launched in 2011, BioSpeedia develop and manufacture French test kits for rapid screening and diagnosis of Covid-19, to protect and allow your community to function and create a safe environment to reopen and keep it open.

BioSpeedia also signed a strategic and Technologic Partnership with SICPA to offer a service layer to allow secured traveling in addition to our screening product line.

An Industrial Partnership has been signed as well with Delpharm, who manufacture in France our rapid test. We have the first and only French fully automated production line for “lateral flow” testing.

BioSpeedia worldwide sales and distribution, product registration, liaising with regulatory authorities, logistics and shipping is handled by our distribution arm, BioVitess Ltd. a UK based sister company.

BioSpeedia is also having subsidiaries in the United States with BioSpeedia LLC and in Switzerland with BioSpeedia International.


We are a spin-off from Institut Pasteur and have a license giving us access to the main reagents.


BioSpeedia manufacture in France at the Delpharm Biotech factory in Lyon and will have soon the first and only French fully automated production line for “lateral flow” testing.


BioSpeedia has partnered with the CHU de St Etienne for the design and validation of rapid tests.


BioSpeedia is partnering with SICPA®️ in developing a secured and certified health pass featuring COVID-tests results to allow secured traveling.

Company History

  • Founded in 2011

    The establishment of BioSpeedia

    After spending 3 decades at Institut Pasteur, Yves Germani and Evelyne Begaud, establish the Company as the official spin-off from the premier French Institute.

  • 2014

    Grant from Aide au Partenariat Technologique

  • 2017

    Developed fast and accurate lateral flow diagnostic kit to detect Neisseria meningitidis (Menincococcus)

    Developed a diagnostic kit to rapidly detect bacterial meningitis using spinal fluid and subsequently using urine samples.

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antibody test kit

    COVID19SEROSpeed-IgM-IgG Test is an immunochromatographic assay designed for the qualitative detection and differentiation of specific IgM and IgG antibodies to coronavirus 2019-nCoV or SARS-CoV-2 in human fingertip blood samples

  • 2020

    Seal of Excellence from H2020

    For COVID-19 Response

  • 2020

    Received CE Mark for our SARS-CoV-2 rapid antigen test kit

    COVID-19SPEEDAntigen Test is a colloidal gold enhanced double antibody sandwich immunoassay for qualitative determination of SARS-CoV-2 antigen in human nasal swabs.